Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis

NCT06688253 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT06688253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06688253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis
Lead sponsor
Rambam Health Care Campus
Phase
Phase 4
Overall status
Not yet recruiting
Start date
November 15, 2024
Completion date
March 30, 2025
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis crisis